[Signal Transduction and Targeted Therapy] Scientists applied 3D patient-derived, metastatic human mammary organoids to model apoptosis resistance, necroptosis, and inflammatory signaling using single-cell CITE-sequencing, time-lapse live cell brightfield, and immunofluorescent confocal microscopy, as well as biochemical approaches.

[Cancer Research] Researchers revealed that commensal dysbiosis-associated loss of microbial bile acid (BA) metabolism elevates primary BAs and promotes HR+ metastatic progression through prostaglandin E2 signaling.

[Cancer Immunology Research] Using single-cell and spatial transcriptomes, investigators identified, at the single-cell level, a subpopulation of macrophages related to T cell expansion during immunotherapy, characterized by high expression of high-temperature requirement A1 (HTRA1), and correlated with clinical and immunotherapy outcomes in TNBC.

[Cell Death & Disease] The authors demonstrated that iroquois homeobox 1 (IRX1) is downregulated in breast cancer tissues and cell lines due to promoter hypermethylation.

[Journal of Nanobiotechnology] Scientists highlighted the potential of red blood cell-derived extracellular vesicles as a biocompatible delivery system enabling combined therapy and offering a promising strategy to overcome current limitations in TNBC treatment.

[Journal of Translational Medicine] Researchers investigated the role of NSUN2 in breast cancer and the underlying mechanisms. They found that NSUN2 accelerates the progression of breast cancer by promoting glycolysis and immune evasion.

[Expert Opinion on Drug Delivery] The authors discuss ligand-functionalized liposomes for active targeting in breast cancer. Surface modification with antibodies, peptides, aptamers, carbohydrates, and small molecules enables selective binding to overexpressed receptors, improving cellular uptake and intracellular drug delivery.

[Mammogen (Globe Newswire)] Mammogen announced an up to $30 million institutional Series A equity financing led by a major US public retirement system. The financing is structured to support Mammogen’s next phase of growth, including its pivotal prospective clinical program and commercialization expansion.

[Josep Carreras Leukemia Research Institute] Dr. Josep Maria Ribera, head of the Acute Lymphoblastic Leukaemia laboratory at the Josep Carreras Leukemia Research Institute, has been awarded the prestigious EHA Clinical Excellence Award 2026.

[Nature] Investigators developed xenograft inflammation–recovery models and performed single-cell multiomics on xenografted human hematopoietic stem cells.

[Leukemia] Scientists studied sphingosine-1-phosphate and FLT3 co-targeting to overcome FLT3 inhibitor resistance in NRAS-mutated FLT3-ITD AML cells.

[Leukemia] Researchers reported the design of a novel anti-hCD7 mAb-based antibody-drug conjugate carrying a BCL-XL-selective inhibitor that circumvents this significant limitation.